Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients?

Clinical and Experimental Nephrology

Volumn 14, Issue 3, 2010, Pages 214-221

  El Shafey, Eid M ^a   Abdou, Said H ^b   Shareef, Mohamed M ^c  

^a TANTA UNIVERSITY HOSPITAL   (Egypt)

^b TANTA UNIVERSITY   (Egypt)

^c TANTA UNIVERSITY   (Egypt)

Author keywords

(IVC) Mycophenolate mofetil; Intravenous cyclophosphamide; Proliferative lupus nephritis

Indexed keywords

COMPLEMENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SOLUBLE INTERLEUKIN 2 RECEPTOR; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ADULT; ANEMIA; ARTICLE; BLOATING; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG WITHDRAWAL; EGYPT; EPIGASTRIC PAIN; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOCRIT; HERPES ZOSTER; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MENSTRUAL IRREGULARITY; NAUSEA; NECROTIZING FASCIITIS; PHARYNGITIS; PNEUMONIA; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; REMISSION; SCORING SYSTEM; THRUSH; TINEA; TREATMENT DURATION; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VOMITING; INTRAVENOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 77956632505     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-010-0270-7     Document Type: Article

References (31)

1. Vu TV, Escalante A. A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease. J Rheumatol. 1999;26:2595-2601
2. Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med. 1996;156:1337-1344
3. Churg JSL. Lupus nephritis. In: Churg JSL, editor. Renal disease, classification and atlas of glomerular diseases. 1st ed. New York: Igaku-Shoin; 1982. p. 127-149
4. Mitjavila F, Pac V, Moga I, et al. Clinicopathological correlations and prognostic factors in lupus nephritis. Clin Exp Rheumatol. 1997;15:625-631
5. Yoo CW, Kim MK, Lee HS. Predictors of renal outcome in diffuse proliferative lupus nephropathy: data from repeat renal biopsy. Nephrol Dial Transplant. 2000;15:1604-1608
6. Hurtado A, Asato C, Escudero E, et al. Clinicopathologic correlations in lupus nephritis in Lima, Peru. Nephron. 1999;83:323-330
7. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only Arthritis Rheum. 1991 34: 945-950
8. Gourley MF, Austin HA III, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549-557
9. Boumpas DT, Austin HA III, Fessler BJ, et al. Systemic lupus erythematosus: emerging concepts. Part I. Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med. 1995;122:940-950
10. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation. 1997;63:39-47.
11. Van Bruggen MC, Walgreen B, Rijke TP, Berden JH. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol. 1998;9:1407-1415
12. Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations. J Am Soc Nephrol. 1999;10:833-839
13. Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis. 1998;31:213-217
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
15. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulo-nephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-250 [published erratum in J Am Soc Nephrol. 2004; 15:835-6.
16. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461-470
17. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of sex sytems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989;32:1107-1118
18. Kim MY, Buyon JP, Petri M, et al. Equivalence trials in SLE research: issues to consider. Lupus. 1999;8:620-626
19. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. J Am Soc Nephrol. 2009;20:1103-1112
20. Chan TM, Li FK, Tang C, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med. 2000;343:1156-1162
21. Gladman DD, Goldsmith CH, Urowitz MB, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: International validation. J Rheumatol. 1994;21:1468-1471
22. Moore RA, Derry S. Systematic review and meta-analysis of randomized trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther. 2006;8:R182.
23. Walsh M, James M, Jayne D, Tonelli M, Manns BJ. Hemmelgarn BR: Mycophenolate mofetil for induction therapy of lupus nephritis: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2007;2:968-975
24. Zhu B, Chen N,Lin Y,Ren H, Zhang W, Wang W, et al. Mycophenolate mofetil in induction and maintenance therapy ofsevere lupus nephritis: A meta-analysis of randomized controlled trials Nephrol Dial Transplant. 2007 22 1933-1942
25. Barr RG, Seliger S, Appel GB, et al. Prognosis in proliferative lupus nephritis: The role of socio-economic status and race/ethnicity. Nephrol Dial Transplant. 2003;18:2039-2046
26. Contreras G, Lenz O, Pardo V, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int. 2006;69:1846-1851
27. Adler M, Chambers S, Edwards C, et al. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology. 2006;45:1144-1147
28. Fernández M, Alarcón GS, Calvo-Alén J, LUMINA Study Group, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum. 2007;57:576-584
29. Contreras G, Pardo V, Leclerq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971-980
30. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: longterm followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46:995-1002.
31. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076-1084